Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 2238-2239, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacobsen, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacobsen, D. W.
(Clinical Chemistry. 1998;44:2238-2239.)
© 1998 American Association for Clinical Chemistry, Inc.

Editorial

Acquired Hyperhomocysteinemia in Heart Transplant Recipients

Donald W. Jacobsen

Department of Cell Biology, FF4-07, The Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, Fax (216) 445-5480, E-mail jacobsd@cesmtp.ccf.org

The etiology and clinical significance of hyperhomocysteinemia are under intense investigation. Although non-genetic (1) and genetic (2)(3)(4) factors influence plasma homocysteine concentrations, the etiology of moderate to intermediate hyperhomocysteinemia (15–50 µmol/L), commonly found in patients with coronary artery disease, cerebrovascular disease, peripheral vascular disease, and in patients with end-stage renal disease, is often unclear. The causes are likely to be multifactorial, involving both acquired and genetic components. There is strong evidence that hyperhomocysteinemia is an independent risk factor for cardiovascular disease (1)(5)(6)(7), but there are conflicting reports as well (8)(9)(10). Some individuals cannot afford to wait the several years it may take before definitive results are available from intervention studies. These include patients with end-stage renal disease, renal transplant recipients, and heart transplant recipients. Immediate treatment of their hyperhomocysteinemia may be more prudent.

Homocysteine is an easily modifiable risk factor that responds well to benign intervention strategies using water-soluble B complex vitamins (11)(12)(13). It is derived from methionine in a three-step pathway (14). Homocysteine may be cytotoxic, and low intracellular steady-state concentrations are maintained by remethylation back to methionine (to complete the cycle), conversion to cystathionine in the transsulfuration pathway, and export to the circulation. The transsulfuration pathway appears to be highly organ-specific (14), and the betaine-dependent remethylation pathway is found only in the liver and kidneys (15. . . [Full Text of this Article]


Footnotes


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.